LFG
NPCE icon

Larson Financial Group’s Neuropace NPCE Stock Holding History

Larson Financial Group’s Portfolio NPCE Stock Details NPCE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		$355 Buy
27
+16
+145% +$240 ﹤0.01% 3379
2025
Q4 		$170 Buy
+11
New +$147 ﹤0.01% 3293
2025
Q3 		– Sell
-1,033
Closed -$11.5K – 3578
2025
Q2 		$11.5K Buy
1,033
+7
+0.7% +$88 ﹤0.01% 1743
2025
Q1 		$12.6K Buy
+1,026
New +$12.8K ﹤0.01% 1548

Other funds holding NPCE

PCH
Polar Capital Holdings London, United Kingdom $28.2B AUM 115.26% 1-Year Est. Return
SCM
Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
FLAM
First Light Asset Management Edina, Minnesota $1.12B AUM 114.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
DCM
Driehaus Capital Management Chicago, Illinois $13.6B AUM 173.98% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $303B AUM 30.15% 1-Year Est. Return
AC
Armistice Capital New York $5.62B AUM 36.06% 1-Year Est. Return

Larson Financial Group's NPCE Position: Q1 2026 in Review

Larson Financial Group increased its Neuropace (NPCE) stake by 145% in Q1 2026, buying an estimated $240 and bringing the position to 27 shares worth $355. The position accounts for ﹤0.01% of the portfolio, ranked #3379.

Larson Financial Group first reported a position in NPCE in Q1 2025 and has held it in 4 quarters since. The position peaked at $12.6K in Q1 2025. 113 funds tracked by Wall St. Rank hold NPCE as of Q1 2026.

  • Larson Financial Group held 27 shares of Neuropace worth $355 as of Q1 2026.
  • Larson Financial Group bought 16 Neuropace shares in Q1 2026, an estimated $240.
  • Neuropace made up ﹤0.01% of Larson Financial Group's portfolio in Q1 2026, its #3379 holding.
  • Larson Financial Group first reported a position in Neuropace in Q1 2025 and has held it in 4 quarters since.
  • Larson Financial Group's Neuropace position peaked at $12.6K in Q1 2025.
  • 113 funds tracked by Wall St. Rank held Neuropace as of Q1 2026.

Based on Larson Financial Group's 13F filing for Q1 2026, filed 15 May 2026.